Autonomix Medical Inc 2026年季度报告

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 10-Q 47-1607810(I.R.S. Employer Identification No.) Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12months (or for such shorter periods as the registrant was required to file such reports) and (2)has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T during thepreceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ PART I FINANCIAL INFORMATION Item 1.Condensed Financial Statements PART II OTHER INFORMATION Autonomix Medical, Inc.Notes to the Unaudited Condensed Financial Statements Note 1–Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies Description of the Business Autonomix Medical, Inc. (“we,” “our,” the “Company”) is a medical device company organized as a Delaware corporation on June 10,2014. The Company is a pre-revenue, clinical stage life sciences company focused on advancing innovative technologies for sensing and The Company is developing a proprietary platform intended to enable real-time nerve signal detection and targeted energy delivery, withthe goal of improving the precision and safety of interventional procedures addressing conditions associated with nerve dysfunction. The Liquidity and Going Concern For the three and nine months ended December 31, 2025 and 2024, the Company incurred net losses of $3.3 million and $2.7 million,respectively, and $14.0 million and $8.2 million, respectively. For the nine months ended December 31, 2025 and 2024, the Company had netcash flows used in operating activities of $9.4 million and $5.7 million, respectively. The Company had no revenues for the three and ninemonths ended December 31, 2025 and 2024, respectively, and an accumulated deficit of $64.4 million, working capital of $8.5 million and The Company estimates its current cash resourcesare sufficient to fund its operations into but not beyond the third calendar quarter of2026. The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatoryclearance for its products currently under development and commercializing and generating revenues from products under development. Thereis no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date thefinancial statements are issued. The accompanying condensed financial statements have been prepared on a going concern basis and do not Basis of Presentation The accompanying condensed interim financial statements are unaudited. These unaudited condensed interim financial statements havebeen prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financialinformation. Accordingly, they do not include all the information and notes required by generally accepted accounting principles in the UnitedStates of America (“GAAP”) for complete financial statements. The Company’s fiscal year end is March 31st. These unaudited condensedinterim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year endedMarch 31, 2025 as found in the Annual Report in the Company's Form 10-K filed with the SEC on May 29, 2025. In the opinion ofmanagement, the unaudited condensed interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) Use of Estimates in Financial Statement Presentation The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to makeestimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reportedamounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but not yetbilled by contract manufacturers, engineers and research organizations and the valuation of equity related instruments. Although the Company Table of Contents Cash and Cash Equivalents The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cashequivalents.Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $250 Offering and Financing Costs Offering costs consist of professional costs incurred through the balance sheet date that are dire